Protara Therapeutics Inc. (NASDAQ: TARA) is 78.78% higher on its value in year-to-date trading and has touched a low of $8.80 and a high of $67.08 in the current 52-week trading range. The TARA stock was last observed hovering at around $30.80 in the last trading session, with the day’s loss setting it -1.48% off its average median price target of $45.00 for the next 12 months. It is also 34.84% off the consensus price target high of $45.00 offered by 1 analysts, but current levels are 34.84% higher than the price target low of $45.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $29.32, the stock is -19.65% and -10.61% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 36499.0 and changing -4.81% at the moment leaves the stock 26.89% off its SMA200. TARA registered 74.44% gain for a year compared to 6-month gain of 66.55%. The firm has a 50-day simple moving average (SMA 50) of $36.43 and a 200-day simple moving average (SMA200) of $28.56.
The stock witnessed a -42.64% loss in the last 1 month and extending the period to 3 months gives it a 27.48%, and is -1.97% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 16.19% over the week and 19.81% over the month.
Distance from 52-week low is 233.18% and -56.29% from its 52-week high.
Protara Therapeutics Inc. (TARA) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Protara Therapeutics Inc. (TARA) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 1.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Protara Therapeutics Inc. quarterly earnings per share for the current quarter are estimated at -$0.46.The EPS is expected to grow by 34.20% this year.
Protara Therapeutics Inc. (TARA) Top Institutional Holders
23 institutions hold shares in Protara Therapeutics Inc. (TARA), with 1.21M shares held by insiders accounting for 20.67% while institutional investors hold 72.17% of the company’s shares. The shares outstanding are 5.56M, and float is at 4.20M with Short Float at 0.34%. Institutions hold 57.25% of the Float.
Protara Therapeutics Inc. (TARA) Insider Activity
A total of 13 insider transactions have happened at Protara Therapeutics Inc. (TARA) in the last six months, with sales accounting for 0 and purchases happening 13 times.